Carolina Ibanez-Ventoso's questions to Allogene Therapeutics Inc (ALLO) leadership • Q4 2024
Question
Carolina Ibanez-Ventoso, on for Ben Burnett from Stifel, asked about the specific timing of the MRD conversion measurement for the mid-2025 interim analysis of the cema-cel trial.
Answer
Dr. Zachary Roberts, EVP of R&D and CMO, responded that the company has not disclosed the exact timing of the MRD measurement for the lymphodepletion decision, noting it is one of several factors that will be assessed.